Food and Drug Administration. Guidance for Industry: Diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring, MD: Food and Drug Administration, 2008.
2.
FrederichR, AlexanderJH, FiedorekFT, et al.A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med, 2010; 122:16–27.
3.
JoseT, InzucchiSE. Cardiovascular effects of the DPP-4 inhibitors. Diab Vasc Dis Res, 2012; 9:109–116.
4.
UssherJR, DruckerDJ. Cardiovascular biology of the incretin system. Endocr Rev, 2012; 33:187–215.
5.
ScheenAJ. Cardiovascular effects of gliptins. Nat Rev Cardiol, 2013; 10:73–84.
6.
DhindsaS, JialalI. Potential anti-atherosclerotic effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus. Curr Diab Rep, 2014; 14:463.
7.
WhiteWB, CannonCP, HellerSR, et al.Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med, 2013; 369:1327–1335.
8.
WhiteWB. Heart failure hospitalizations seen in patients with prior heart failure. Endocrine Today, 2013; 11:39–40.
9.
BaettaR, CorsiniA. Pharmacology of dipeptidyl peptidase-4 inhibitors: Similarities and differences. Drugs, 2011; 71:1441–1467.
10.
van PoppelPC, NeteaMG, SmitsP, et al.Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care, 2011; 34:2072–2077.
11.
KubotaY, MiyamotoM, TakagiG, et al.The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. J Korean Med Sci, 2012; 27:1364–1370.
12.
BarbieriM, RizzoMR, MarfellaR, et al.Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis, 2013; 227:349–354.
13.
MakdissiA, GhanimH, VoraM, et al.Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab, 2012; 97:3333–3341.
14.
MatikainenN, ManttariS, SchweizerA, et al.Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia, 2006; 49:2049–2057.
15.
TremblayAJ, LamarcheB, DeaconCF, et al.Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab, 2011; 13:366–373.
